DOCSLIB.ORG

Updates in Uterine and Vulvar Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Management of GYN Malignancies Junzo Chino MD Duke Cancer Center ASTRO Refresher 2015 Disclosures • None Learning Objectives • Review the diagnosis, workup, and management of: – Cervical Cancers – Uterine Cancers – Vulvar Cancers Cervical Cancer Cervical Cancer • 3rd most common malignancy in the World • 2nd most common malignancy in women • The Leading cause of cancer deaths in women for the developing world • In the US however… – 12th most common malignancy in women – Underserved populations disproportionately affected > 6 million lives saved by the Pap Test “Diagnosis of Uterine Cancer by the Vaginal Smear” Published Pap Test • Start screening within 3 years of onset of sexual activity, or at age 21 • Annual testing till age 30 • If no history of abnormal paps, risk factors, reduce screening to Q2-3 years. • Stop at 65-70 years • 5-7% of all pap tests are abnormal – Majority are ASCUS Pap-test Interpretation • ASCUS or LSIL –> reflex HPV -> If HPV + then Colposcopy, If – Repeat in 1 year • HSIL -> Colposcopy • Cannot diagnose cancer on Pap test alone CIN • CIN 1 – low grade dysplasia confined to the basal 1/3 of epithelium – HPV negative: repeat cytology at 12 months – HPV positive: Colposcopy • CIN 2-3 – 2/3 or greater of the epithelial thickness – Cold Knife Cone or LEEP • CIS – full thickness involvement. – Cold Knife Cone or LEEP Epidemiology • 12,900 women expected to be diagnosed in 2015 – 4,100 deaths due to disease • Median Age at diagnosis 48 years Cancer Statistics, ACS 2015 Risk Factors: Cervical Cancer • Early onset sexual activity • Multiple sexual partners • Hx of STDs • Multiple pregnancy • Immune suppression (s/p transplant, HIV) • Tobacco HPV • The human papilloma virus is a double stranded DNA virus • The most common oncogenic strains are 16, 18, 31, 33 and 45. • 16 and 18 account for 70% of US cases, with slightly less prevalence worldwide. HPV: oncogenesis • E6 binds to p53, inhibiting apoptosis and encouraging immortality • E7 binds to Rb, thus activating the cell cycle and promoting uncontrolled proliferation Yim & Park, Cancer Res Treat 2005 HPV: prevalence • ~50% of women will be exposed to HPV within 4 years of the onset of sexual activity • 2 year clearance rate of HPV is 90% with only 5% developing any cytological abnormality Schiffman et al, Lancet 2007 Vaccine • Cervarix: HPV 16, 18 • Gardasil: HPV 6, 11, 16, 18 – Most common in US • Gardasil 9 just approved (6, 11, 16, 18, 31, 33, 45, 52, 58) • All approved by FDA • All are a series of 3 injections over 6 months • Neither prevent or speed clearance of an existing HPV infection Quadrivalent Vaccine Efficacy Time until the Development of High-Grade Time until the Development of High-Grade Cervical Disease Associated with HPV-16, HPV-18 Cervical Disease Associated with any HPV The Future II study Group. NEJM 2007;356:1915 HPV vaccination rates ~32% Jemal A., et al. J Natl Cancer Inst. 2013 Feb 6;105(3):175-201 FIGO (2009) • Stage I – confined to the Uterus – IA1: 3mm or less stromal invasion, 7mm or less horizontal spread – IA2: >3mm to 5mm invasion, 7mm or less horizontal spread – IB1: 4.0 cm or less – IB2: >4cm • Stage II – local extension – IIA1: involves upper 2/3 of vagina, 4cm or less – IIA2: involves upper 2/3 of vagina, >4cm in size – IIB: parametrial involvement • Stage III – regional extension – IIIA: involves lower 1/3 of vagina – IIIB: extends to pelvic side wall or hydronephrosis seen on imaging • Stage IVA: invades bladder, rectum, or extends beyond true pelvis • Stage IVB: distant mets AJCC • T stage Mirrors FIGO, however adds N category • N1 = regional nodes (AJCC IIIB) • M1 = distant mets, and paraaortic nodes (AJCC IVB) Imaging • The only imaging allowed to affect FIGO stage is IVP (CT can be used to look for hydro) • MRI is the most accurate for determining local extent (~90% accurate for parametrial/vaginal involvement) • PET is the most accurate for nodal staging (sensitivity ~85%, specificity ~95%) Histology • >90% squamous cell • 7 - 10% adenocarcinoma • 1 - 2 % clear cell, small cell Para-Aortic Nodes Para-Aortic Common Iliac Nodes Dissection usually only extends to Presacral Nodes the IMA Internal Iliac Nodes External Iliac Nodes Obturator Nodes Risk of Pelvic LN Risk of nodes with <4mm invasion (stage IA1) is <5%, therefore nodal dissection or elective RT is not necessary Size Stage Ib Stage IIa <1 cm 18% 27% 2 - 3 cm 22% 18% 4 - 5 cm 35% 43% >6 cm 50% 38% Piver, et al. Obstet Gynecol. 1975 Nov;46(5):507-10. Lymph Node Distributions • Stage IB - IIA Cervix Benedetti-Panici, et al. Gynecol Oncol 1996;62:19–24 Lymph Node Distribution • Locally Advanced Cervix Benedetti-Panici, et al. Gynecol Oncol 1996;62:19–24 Locating the Obturator Nodes Find Obturator Groove (containing obturator nerve and vessels) Locating the Obturator Nodes Follow vessels superiorly until they enter the pelvis Para-aortic Lymph Node Involvement Stage IB Stage IIA Stage IIB Stage IIIA Stage IIIB Stage IV Lagasse 6% 18% 33% 0% 31% 25% (GOG, 1980) 8/143 4/22 19/58 0/3 19/61 1/4 Nelson — — 16% — 46% — (1977) 5/31 13/28 Piver — — 13% — 37% 57% (1981) 6/46 18/49 4/7 Wharton 0% 0% 21% — 33% (1977) 0/21 (0) 0/10 10/47 14/42 Risk of PA Nodes also increases with ~5% per pelvic node involved, though with 4+ nodes the risk is >40% Sakuragi et al, Cancer, 1999 Treatment Overview FIGO Treatment IA1 Cervical conization or extrafascial hysterectomy Consider vaginal radical trachelectomy for fertility sparing IA2 Modified radical hysterectomy & PLND IB1 IB2 MRH & PLND only in well selected Pts otherwise CTRT + Brachy IIA1 IIA2 Definitive chemoradiation IIB (EBRT + weekly cisplatin IIIA brachytherapy boost) IIIB IVA IVB Chemotherapy +/- palliative radiotherapy Modified Radical Hysterectomy Randomized Data: Early Stage Disease Surgery vs RT Milan trial: Radical surgery vs. XRT n = 337 R Radical hysterectomy + PLND (PA LN FIGO Ib-IIa cervical A sampling if suspicious) cancer • 50.4 Gy adjuvant XRT if > pT2a, cut- N through, +LN, <3 mm uninvolved D cervical stroma Years: 1986-1991 O 54% in Surgery arm received RT M Definitive radiation I • WPRT (median dose 47 Gy) • 45 Gy to PA nodes if +LN Z • 5-10 Gy boost to +LN E • LDR brachy (median cumulative point A dose 76 Gy) • Primary outcome: 5-yr OS and complication rate • Median f/u: 87 months Landoni, et al. Lancet 1997; 350:535 No difference in OS or DFS G2-3 toxcity worse with RH (28% vs 12%, SS) Edema 9% if RH + PORT % surviving % surviving Time since treatment (mo) Time since treatment (mo) Take Home – Outcomes the same but toxicity worse with RH in bulkier early stage disease Landoni et al, Lancet 1997 Randomized Data: Early Stage Disease Post-hysterectomy RT vs NFT RT vs CTRT GOG 92: Postop XRT for Stage IB, intermediate risk n = 277 R FIGO IB cervical ca No further tx s/p rad hys & PLND A with risk factors N Intermediate Risk (see inset) D O M Years: 1988-1995 I Z WPRT (46 Gy/23 fx or 50.8 Gy/28 fx) Exclusion criteria: • +LN E • Primary outcome: Recurrence risk/recurrence-free interval • Secondary outcomes: OS Sedlis et al, Gyn Onc 1999 • Median f/u: 5 years for surviving patients Rotman, et al. IJROBP 2006 May 1;65(1):169-76 Not powered for Survival GOG 109, SWOG 8797, RTOG 9112: Postop RT vs. RT+CDDP/5-FU for high-risk n = 243 R FIGO IA2 – IIA high- WPRT risk cervical cancer A • 49.3 Gy/29 fractions (EBRT) s/p hys & PLND N • 45 Gy to PA field (1.5 Gy/fx) if high • +LN &/or common iliac LN+ • +margin &/or D • +parametria O M I Years: 1991-1996 WPRT + CDDP/5-FU (4 cycles) Z • Bolus CDDP (70 mg/m2) & 5-FU E (4000 mg/m2 in 4 days) Q3 weeks • Cycles 1 & 2 with XRT • Primary outcomes: PFS, OS • Secondary outcomes: Toxicity • Median f/u: 3.5 years Peters et al, JCO 2000 Improved PFS with XRT+CDDP/5-FU PFS: 80% with chemoXRT vs. 63% with XRT Adjusted HR 2.01 (p = 0.003) free survival free - Progression Peters et al, JCO 2000 Improved OS with XRT+CDDP/5-FU OS: 81% with chemoXRT vs. 71% with XRT Adjusted HR 1.96 (p = 0.007) Overall survival Overall Peters et al, JCO 2000 Adjuvant RT conclusions • Women with large tumors, deep invasion, and/or LVSI should be considered for adjuvant RT. • Women with positive margins, nodes or parametrium should be offered radiation with chemo. Ongoing trials • Intermediate risk – GOG 263: RT vs CTRT • High risk – RTOG 0724: CTRT +/- adjuvant chemotherapy (4 cycles carbo/paclitaxel) • TIME-C/RTOG 1203 – 3D vs IMRT for postoperative cervix/uterine Advanced Disease Definitive CTRT and Brachytherapy RTOG 90-01: WPRT/Chemo vs. Pelvic/PA XRT n = 389 R FIGO IIB-IVA 45 Gy to pelvis and para-aortic LN cervical cancer or A (EFRT) LDR brachy IB-IIA cervical N cancer if tumor > 5 cm or +LN D O Cumulative point A dose > 85 Gy Years: 1990-1997 M Exclusion criteria: • Pos. PA LN I 45 Gy to pelvis with concurrent • Disease outside Z CDDP/5-FU LDR brachy pelvis • 3 cycles chemo (Q3 weeks) • Prior tx for E • 75 mg/m2 cisplatin cervical ca • 4000 mg/m2 5-FU over 4 days • Primary outcome: OS • Secondary outcomes: DFS, LR, PA node recurrence, distant metastases • Median f/u: 43 months (NEJM 1999); 79 months for surviving patients (JCO 2004) Morris et al, NEJM 1999 and Eifel et al, JCO 2004 Toxicity • Acute toxicity worse with CTRT – 11% G4-5 toxicity with CTRT vs 1% RT – Difference was largely due to Heme toxicity • Late toxicity no different – 14% in both arms Improved DFS with ChemoXRT 67% 40% LR recurrence: 19% with chemoXRT vs.
Recommended publications
  • Treating Cervical Cancer If You've Been Diagnosed with Cervical Cancer, Your Cancer Care Team Will Talk with You About Treatment Options

    Treating Cervical Cancer If You've Been Diagnosed with Cervical Cancer, Your Cancer Care Team Will Talk with You About Treatment Options

    cancer.org | 1.800.227.2345 Treating Cervical Cancer If you've been diagnosed with cervical cancer, your cancer care team will talk with you about treatment options. In choosing your treatment plan, you and your cancer care team will also take into account your age, your overall health, and your personal preferences. How is cervical cancer treated? Common types of treatments for cervical cancer include: ● Surgery for Cervical Cancer ● Radiation Therapy for Cervical Cancer ● Chemotherapy for Cervical Cancer ● Targeted Therapy for Cervical Cancer ● Immunotherapy for Cervical Cancer Common treatment approaches Depending on the type and stage of your cancer, you may need more than one type of treatment. For the earliest stages of cervical cancer, either surgery or radiation combined with chemo may be used. For later stages, radiation combined with chemo is usually the main treatment. Chemo (by itself) is often used to treat advanced cervical cancer. ● Treatment Options for Cervical Cancer, by Stage Who treats cervical cancer? Doctors on your cancer treatment team may include: 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 ● A gynecologist: a doctor who treats diseases of the female reproductive system ● A gynecologic oncologist: a doctor who specializes in cancers of the female reproductive system who can perform surgery and prescribe chemotherapy and other medicines ● A radiation oncologist: a doctor who uses radiation to treat cancer ● A medical oncologist: a doctor who uses chemotherapy and other medicines to treat cancer Many other specialists may be involved in your care as well, including nurse practitioners, nurses, psychologists, social workers, rehabilitation specialists, and other health professionals.
  • WHO Guidelines for Treatment of Cervical Intraepithelial Neoplasia 2–3 and Adenocarcinoma in Situ

    WHO Guidelines for Treatment of Cervical Intraepithelial Neoplasia 2–3 and Adenocarcinoma in Situ

    WHO guidelines WHO guidelines for treatment of cervical intraepithelial neoplasia 2–3 and adenocarcinoma in situ Cryotherapy Large loop excision of the transformation zone Cold knife conization WHO guidelines WHO guidelines for treatment of cervical intraepithelial neoplasia 2–3 and adenocarcinoma in situ: cryotherapy, large loop excision of the transformation zone, and cold knife conization Catalogage à la source : Bibliothèque de l’OMS WHO guidelines for treatment of cervical intraepithelial neoplasia 2–3 and adenocarcinoma in situ: cryotherapy, large loop excision of the transformation zone, and cold knife conization. 1.Cervical Intraepithelial Neoplasia – diagnosis. 2.Cervical Intraepithelial Neoplasia – therapy. 3.Cervical Intraepithelial Neoplasia – surgery. 4.Adenocarcinoma – diagnosis. 5.Adenocarcinoma – therapy. 6.Cryotherapy – utilization. 7.Conization – methods. 8.Uterine Cervical Neoplasms – prevention and control. 9.Guideline. I.World Health Organization. ISBN 978 92 4 150677 9 (Classification NLM : WP 480) © World Health Organization 2014 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
  • Prognostic Factors for Patients with Early-Stage Uterine Serous Carcinoma Without Adjuvant Therapy

    Prognostic Factors for Patients with Early-Stage Uterine Serous Carcinoma Without Adjuvant Therapy

    J Gynecol Oncol. 2018 May;29(3):e34 https://doi.org/10.3802/jgo.2018.29.e34 pISSN 2005-0380·eISSN 2005-0399 Original Article Prognostic factors for patients with early-stage uterine serous carcinoma without adjuvant therapy Keisei Tate ,1 Hiroshi Yoshida ,2 Mitsuya Ishikawa ,1 Takashi Uehara ,1 Shun-ichi Ikeda ,1 Nobuyoshi Hiraoka ,2 Tomoyasu Kato 1 1Department of Gynecology, National Cancer Center Hospital, Tokyo, Japan 2Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan Received: Nov 29, 2017 ABSTRACT Revised: Jan 15, 2018 Accepted: Jan 26, 2018 Objective: Uterine serous carcinoma (USC) is an aggressive type 2 endometrial cancer. Data Correspondence to on prognostic factors for patients with early-stage USC without adjuvant therapy are limited. Keisei Tate This study aims to assess the baseline recurrence risk of early-stage USC patients without Department of Gynecology, National Cancer adjuvant treatment and to identify prognostic factors and patients who need adjuvant therapy. Center Hospital, 5 Chome-1-1 Tsukiji, Chuo-ku, Methods: Sixty-eight patients with International Federation of Gynecology and Obstetrics Tokyo 104-0045, Japan. (FIGO) stage I–II USC between 1997 and 2016 were included. All the cases did not undergo E-mail: [email protected] adjuvant treatment as institutional practice. Clinicopathological features, recurrence Copyright © 2018. Asian Society of patterns, and survival outcomes were analyzed to determine prognostic factors. Gynecologic Oncology, Korean Society of Results: FIGO stages IA, IB, and II were observed in 42, 7, and 19 cases, respectively. Median Gynecologic Oncology follow-up time was 60 months. Five-year disease-free survival (DFS) and overall survival This is an Open Access article distributed under the terms of the Creative Commons (OS) rates for all cases were 73.9% and 78.0%, respectively.
  • Cervical Cancer

    Cervical Cancer

    Cervical Cancer Ritu Salani, M.D., M.B.A. Assistant Professor, Dept. of Obstetrics & Gynecology Division of Gynecologic Oncology The Ohio State University Estimated gynecologic cancer cases United States 2010 Jemal, A. et al. CA Cancer J Clin 2010; 60:277-300 1 Estimated gynecologic cancer deaths United States 2010 Jemal, A. et al. CA Cancer J Clin 2010; 60:277-300 Decreasing Trends of Cervical Cancer Incidence in the U.S. • With the advent of the Pap smear, the incidence of cervical cancer has dramatically declined. • The curve has been stable for the past decade because we are not reaching the unscreened population. Reprinted by permission of the American Cancer Society, Inc. 2 Cancer incidence worldwide GLOBOCAN 2008 Cervical Cancer New cases Deaths United States 12,200 4,210 Developing nations 530,000 275,000 • 85% of cases occur in developing nations ¹Jemal, CA Cancer J Clin 2010 GLOBOCAN 2008 3 Cervical Cancer • Histology – Squamous cell carcinoma (80%) – Adenocarcinoma (15%) – Adenosquamous carcinoma (3 to 5%) – Neuroendocrine or small cell carcinoma (rare) Human Papillomavirus (HPV) • Etiologic agent of cervical cancer • HPV DNA sequences detected is more than 99% of invasive cervical carcinomas • High risk types: 16, 18, 45, and 56 • Intermediate types: 31, 33, 35, 39, 51, 52, 55, 58, 59, 66, 68 HPV 16 accounts for ~80% of cases HPV 18 accounts for 25% of cases Walboomers JM, Jacobs MV, Manos MM, et al. J Pathol 1999;189(1):12-9. 4 Viral persistence and Precancerous progression Normal lesion cervix Regression/ clearance Invasive cancer Risk factors • Early age of sexual activity • Cigggarette smoking • Infection by other microbial agents • Immunosuppression – Transplant medications – HIV infection • Oral contraceptive use • Dietary factors – Deficiencies in vitamin A and beta carotene 5 Multi-Stage Cervical Carcinogenesis Rosenthal AN, Ryan A, Al-Jehani RM, et al.
  • Colposcopy of the Uterine Cervix

    Colposcopy of the Uterine Cervix

    THE CERVIX: Colposcopy of the Uterine Cervix • I. Introduction • V. Invasive Cancer of the Cervix • II. Anatomy of the Uterine Cervix • VI. Colposcopy • III. Histology of the Normal Cervix • VII: Cervical Cancer Screening and Colposcopy During Pregnancy • IV. Premalignant Lesions of the Cervix The material that follows was developed by the 2002-04 ASCCP Section on the Cervix for use by physicians and healthcare providers. Special thanks to Section members: Edward J. Mayeaux, Jr, MD, Co-Chair Claudia Werner, MD, Co-Chair Raheela Ashfaq, MD Deborah Bartholomew, MD Lisa Flowers, MD Francisco Garcia, MD, MPH Luis Padilla, MD Diane Solomon, MD Dennis O'Connor, MD Please use this material freely. This material is an educational resource and as such does not define a standard of care, nor is intended to dictate an exclusive course of treatment or procedure to be followed. It presents methods and techniques of clinical practice that are acceptable and used by recognized authorities, for consideration by licensed physicians and healthcare providers to incorporate into their practice. Variations of practice, taking into account the needs of the individual patient, resources, and limitation unique to the institution or type of practice, may be appropriate. I. AN INTRODUCTION TO THE NORMAL CERVIX, NEOPLASIA, AND COLPOSCOPY The uterine cervix presents a unique opportunity to clinicians in that it is physically and visually accessible for evaluation. It demonstrates a well-described spectrum of histological and colposcopic findings from health to premalignancy to invasive cancer. Since nearly all cervical neoplasia occurs in the presence of human papillomavirus infection, the cervix provides the best-defined model of virus-mediated carcinogenesis in humans to date.
  • Tumors of the Uterus, Vagina, and Vulva

    Tumors of the Uterus, Vagina, and Vulva

    Tumors of the Uterus, Vagina, and Vulva 803-808-7387 www.gracepets.com These notes are provided to help you understand the diagnosis or possible diagnosis of cancer in your pet. For general information on cancer in pets ask for our handout “What is Cancer”. Your veterinarian may suggest certain tests to help confirm or eliminate diagnosis, and to help assess treatment options and likely outcomes. Because individual situations and responses vary, and because cancers often behave unpredictably, science can only give us a guide. However, information and understanding for tumors in animals is improving all the time. We understand that this can be a very worrying time. We apologize for the need to use some technical language. If you have any questions please do not hesitate to ask us. What are these tumors? Most swellings and tumors of the uterus are not cancerous. The most common in the bitch is cystic endometrial hyperplasia (overgrowth of the inner lining of the uterus) due to hormone stimulation. Sometimes, this reaction is deeper in the muscle layers and is called ‘adenomyosis’. Secondary infection and inflammation then convert the endometrial hyperplasia into pyometra (literally pus in the womb). Cysts and polyps of the endometrium can also be part of the pyometra syndrome or be due to congenital abnormalities. They may persist when the cause is removed and may be multiple. Endometrial cancers may also be multiple. Benign adenomas of the endometrium are rare. Malignant tumors (adenocarcinomas) may spread (metastasize) to lymph nodes and lungs, often when the primary is still small in size.
  • Gynecologic Malignancies J

    Gynecologic Malignancies J

    Gynecologic Malignancies J. Brian Szender 31 March 2016 Outline • Female Cancer Statistics • Uterine Cancer • Adnexal Cancer • Cervical Cancer • Vulvar Cancer Uterine Cancer Endometrial Cancer Uterine Sarcoma Endometrial Cancer • Epidemiology and Risk Factors • Histology • Presentation • Diagnosis • Staging • Therapy • Early • Locally Advanced • Metastatic • Recurrent • Follow-Up • Future Therapy Epidemiology • 60,500 cases expected in 2016 • 25.3 per 100,000 women • 10,470 deaths expected in 2016 Epidemiology Increased Risk Decreased Risk • Age • Progestational Agents • Unopposed Estrogens • Oral Contraceptive Pills • Exogenous • Levonorgestrel IUS • Tamoxifen • Physical Activity • Obesity • Pregnancy • Genetic Risk • Breastfeeding • Lynch Syndrome • Cowden Syndrome Histology • Type I • Endometrioid, well differentiated • Less aggressive • Usually localized • Good Prognosis • Type II • Clear cell, papillary serous, MMMT, poorly differentiated • More aggressive • Likely to spread • Worse Prognosis Histology – Molecular Features Type I Type II • Diploid • Aneuploid • K-ras overexpression • K-ras overexpression • PTEN mutations • P53 overexpression • Microsatellite instability Clinical Presentation • Abnormal Uterine Bleeding • Postmenopausal Uterine Bleeding • Abnormal Vaginal Discharge • Endometrial cells on a pap smear • Bloating/pelvic pressure/pain (if advanced disease) Diagnosis • Ultrasound • Endometrial Biopsy • Hysteroscopy • Dilation and Curettage • Hysterectomy +/- BSO +/- Lymph node sampling Staging wikipedia Therapy – Early
  • UNMH Obstetrics and Gynecology Clinical Privileges Name

    UNMH Obstetrics and Gynecology Clinical Privileges Name

    UNMH Obstetrics and Gynecology Clinical Privileges Name:____________________________ Effective Dates: From __________ To ___________ All new applicants must meet the following requirements as approved by the UNMH Board of Trustees, effective April 28, 2017: Initial Privileges (initial appointment) Renewal of Privileges (reappointment) Expansion of Privileges (modification) INSTRUCTIONS: Applicant: Check off the “requested” box for each privilege requested. Applicants have the burden of producing information deemed adequate by the Hospital for a proper evaluation of current competence, current clinical activity, and other qualifications and for resolving any doubts related to qualifications for requested privileges. Department Chair: Check the appropriate box for recommendation on the last page of this form. If recommended with conditions or not recommended, provide condition or explanation. OTHER REQUIREMENTS: 1. Note that privileges granted may only be exercised at UNM Hospitals and clinics that have the appropriate equipment, license, beds, staff, and other support required to provide the services defined in this document. Site-specific services may be defined in hospital or department policy. 2. This document defines qualifications to exercise clinical privileges. The applicant must also adhere to any additional organizational, regulatory, or accreditation requirements that the organization is obligated to meet. ---------------------------------------------------------------------------------------------------------------------------------------
  • Pretest Obstetrics and Gynecology

    Pretest Obstetrics and Gynecology

    Obstetrics and Gynecology PreTestTM Self-Assessment and Review Notice Medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required. The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication. However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work. Readers are encouraged to confirm the information contained herein with other sources. For example and in particular, readers are advised to check the prod- uct information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. This recommendation is of particular importance in connection with new or infrequently used drugs. Obstetrics and Gynecology PreTestTM Self-Assessment and Review Twelfth Edition Karen M. Schneider, MD Associate Professor Department of Obstetrics, Gynecology, and Reproductive Sciences University of Texas Houston Medical School Houston, Texas Stephen K. Patrick, MD Residency Program Director Obstetrics and Gynecology The Methodist Health System Dallas Dallas, Texas New York Chicago San Francisco Lisbon London Madrid Mexico City Milan New Delhi San Juan Seoul Singapore Sydney Toronto Copyright © 2009 by The McGraw-Hill Companies, Inc.
  • Postoperative Surgical Complications of Lymphadenohysterocolpectomy

    Postoperative Surgical Complications of Lymphadenohysterocolpectomy

    Journal of Medicine and Life Vol. 7, Issue 1, January-March 2014, pp.60-66 Postoperative surgical complications of lymphadenohysterocolpectomy Marin F., Pleşca M., Bordea C.I., Voinea S.C., Burlănescu I., Ichim E., Jianu C.G., Nicolăescu R.R., Teodosie M.P., Maher K., Blidaru A. Department of Surgical Oncology II, " Prof. Dr. Al Trestioreanu " Institute of Oncology, Bucharest Correspondence to: Dr. Bordea Cristian Contact adress: 252 Fundeni St., District 2, Bucharest Phone: 021 227 11 15, E-mail:[email protected] Received: July 19th, 2013 – Accepted: October 22 nd, 2013 Abstract Rationale The current standard surgical treatment for the cervix and uterine cancer is the radical hysterectomy (lymphadenohysterocolpectomy). This has the risk of intraoperative accidents and postoperative associated morbidity. Objective The purpose of this article is the evaluation and quantification of the associated complications in comparison to the postoperative morbidity which resulted after different types of radical hysterectomy. Methods and results Patients were divided according to the type of surgery performed as follows: for cervical cancer – group A- 37 classic radical hysterectomies Class III Piver - Rutledge -Smith ( PRS ), group B -208 modified radical hysterectomies Class II PRS and for uterine cancer- group C -79 extended hysterectomies with pelvic lymphadenectomy from which 17 patients with paraaortic lymphnode biopsy . All patients performed preoperative radiotherapy and 88 of them associated radiosensitization. Discussion Early complications
  • A Ten-Year Retrospective Study of Cervical Conization Followed by Hysterectomy for Various Grades of Cervical Intraepithelial Neoplasia

    A Ten-Year Retrospective Study of Cervical Conization Followed by Hysterectomy for Various Grades of Cervical Intraepithelial Neoplasia

    A ten-year retrospective study of cervical conization followed by hysterectomy for various grades of cervical intraepithelial neoplasia CLAYTON T. SHAW, D 0 Omaha, Nebraska HEINZ 0. OSTERHOLZER, m D Philadelphia, Pennsylvania DAVID M. EVANS, m D Wiesbaden, West Germany They are: (1) visualization of the entire lesion; (2) A ten-year retrospective study of expertise in colposcopy; (3) exclusion of invasive seventy-seven patients from January carcinoma by punch biopsy; (4) adequate cytologic 1971 to December 1980, at the Tripler and colposcopic follow-up; and (5) endocervical Army Medical Center, who curettage. underwent cold knife conization for Conization as a modality, however, is considered cervical intraepithelial neoplasia a definitive therapy for the removal of dysplastic (CIN) followed by hysterectomy, was tissue and is required if the colposcopic examina- performed to determine the tion is inadequate or the endocervical curettage is predictive value of cone clearance positive for CIN. Kolstad stated that conization is regarding residual CIN. Forty-four of the method of choice for carcinoma in situ. He the seventy-seven patients had found a 97 percent cure rate with 1 percent pro- clear cone margins but seven of these gressing to invasive carcinoma and 2 percent to re- forty-four had residual CIN at the current carcinoma in situ. Caglar 9 also studied the time of hysterectomy. This accuracy of the cervical cone. He performed coniza- represented a 15.9 percent tion in thirty-three patients and immediately fol- recurrence rate. Thirty-three patients lowed that procedure with a vaginal hysterectomy. had margins involved at the time of He found that in three patients (9 percent) of the conization, but only fourteen of these uteri specimens had the same diagnosis as the con- (42.4 percent) demonstrated residual ization.
  • Cervical Health Policies Program Description the Breast, Cervical and Colon Health Program (BCCHP) Screens Qualifying Clients for Cervical Cancer

    Cervical Health Policies Program Description the Breast, Cervical and Colon Health Program (BCCHP) Screens Qualifying Clients for Cervical Cancer

    DOH 342-035 July 2018 Cervical Health Policies Program Description The Breast, Cervical and Colon Health Program (BCCHP) screens qualifying clients for cervical cancer. The program is funded through a grant from the Centers for Disease Control and Prevention (CDC). It is administered by the Washington State Department of Health which contracts with Prime Contractors throughout the state to implement the program regionally. The Prime Contractors subcontract with health care providers and organizations to provide direct services to individuals in their communities. BCCHP eligibility and screening policies reflect CDC guidelines. Eligibility & Coverage Gender Definitions for terms used in BCCHP policies • Cisgender - a person whose gender identification and birth sex are the same. • Transgender man - a person who identifies as male with a female-assigned birth sex. • Transgender woman - a person who identifies as female with a male-assigned birth sex. • Genderqueer - A person whose gender identity differs from the gender assigned at birth, but may less clearly defined than a transgender person. • Gender Non-binary - a person who neither identifies as a male nor female with either a female assigned birth sex or a male-assigned birth sex. • Agender – A person who does not identify with any gender. Eligible – Cisgender women and transgender men who meet the following criteria: Must meet all of the following: • Age 40-64 (through the end of the month of client’s 65th birthday). • Age 65+ if the client is not eligible for Medicare or ineligible for Medicare Part B at the time of enrollment. • Age 21-39 if the client is not covered by Family Planning or Title X Clinic funding.